The analysis revealed that desmopressin might significantly decrease the frequency of nocturnal voids , nocturnal urine volume and nocturnal diuresis , potentially result ing in an extended duration of the first sleep period and improved sleep quality .
The adverse effects of desmopressin were similar to those observed in the placebo group .
Conclusions Administered desmopressin was an effective and well-tolerated treatment for nocturia
Purpose The purpose of this analysis was to evaluate the efficacy and safety of desmopressin for the treatment of nocturia .
Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women.
OBJECTIVE The purpose of this study was to investigate the efficacy and safety of oral desmopressin in the treatment of nocturia in women . STUDY DESIGN Women aged 18 years or older with nocturia ( > or=2 voids per night with a nocturia index score > 1 ) received desmopressin ( 0.1 mg , 0.2 mg , or 0.4 mg ) during a 3-week dose-titration period . After a 1-week washout period , patients who responded in this period received desmopressin or placebo in a double-blind fashion for 3 weeks . RESULTS In double-blind phase , 144 patients were r and omly assigned to groups  ( desmopressin , n=72 ; placebo , n=72 ) . For desmopressin , 33 ( 46 % ) patients had a 50 % or greater reduction in nocturnal voids against baseline levels compared with 5 ( 7 % ) patients receiving placebo ( P<.0001 ) . The mean number of nocturnal voids , duration of sleep until the first nocturnal void , nocturnal diuresis , and ratios of nocturnal per 24 hours and nocturnal per daytime urine volumes changed significantly in favor of desmopressin versus placebo ( P<.0001 ) . In the dose-titration phase headache ( 22 % ) , nausea ( 8 % ) , and hyponatremia ( 6 % ) were reported . Two deaths occurred , although neither could be directly associated with the study drug . CONCLUSION Oral desmopressin is an effective and well-tolerated treatment for nocturia in women
The analysis revealed that desmopressin might significantly decrease the frequency of nocturnal voids , nocturnal urine volume and nocturnal diuresis , potentially result ing in an extended duration of the first sleep period and improved sleep quality .
The adverse effects of desmopressin were similar to those observed in the placebo group .
Conclusions Administered desmopressin was an effective and well-tolerated treatment for nocturia
Purpose The purpose of this analysis was to evaluate the efficacy and safety of desmopressin for the treatment of nocturia .